Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

Biopharmaceutics and Pharmacokinetics: Overview

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Examining emergency department utilisation in people with Crystal Arthropathies: a 10-year analysis of visits in a publicly funded universal healthcare system.

EULAR rheumatology open·2026

Same author

CDAI trajectories in patients with rheumatoid arthritis treated with abatacept in real-world.

Advances in rheumatology (London, England)·2026

Same author

Lessons from an early rheumatoid arthritis incident cohort.

Seminars in arthritis and rheumatism·2026

Same author

Emergency department encounters' impacts on First Nations members, families and communities: Results of a thematic analysis of sharing circles in three treaty areas.

Social science & medicine (1982)·2026

Same author

Rheumatology Care Among Indigenous Populations.

Rheumatic diseases clinics of North America·2026

Same author

Intersecting Social Identities and Health in Arthritis: A Latent Class Analysis of the Canadian Longitudinal Study on Aging.

ACR open rheumatology·2026

Search research articles

Related Experiment Video

Updated: May 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Subsequent entry biologics/biosimilars: a viewpoint from Canada.

Anthony S Russell¹, Vandana Ahluwalla, Cheryl Barnabe

¹562 Heritage Medical Centre, University of Alberta, Edmonton, AB T6G2S2, Canada. as.russell@ualberta.ca

Clinical Rheumatology

|August 28, 2012

Summary

Biosimilars offer new rheumatoid arthritis treatment options. Patient safety and long-term therapy outcomes are crucial for evaluating these biologic drugs.

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Related Experiment Videos

Last Updated: May 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Area of Science:

Rheumatology
Pharmacology
Immunology

Background:

The introduction of biosimilars presents novel therapeutic avenues in managing rheumatoid arthritis.
Biologic therapies have revolutionized rheumatoid arthritis treatment, offering targeted approaches.

Purpose of the Study:

To review the key considerations regarding the integration of biosimilars into rheumatoid arthritis treatment paradigms.
To propose a framework for evaluating biosimilar efficacy and safety in clinical practice.

Main Methods:

Literature review of current biosimilar research and regulatory guidelines.
Analysis of existing data on biologic therapies for rheumatoid arthritis.
Synthesis of expert opinions and clinical recommendations.

Main Results:

Biosimilars require rigorous assessment to ensure comparable safety and efficacy to originator biologics.
Establishing clear protocols for monitoring patient response and potential adverse events is essential.

Conclusions:

Prioritizing patient safety is paramount in the adoption of biosimilars for rheumatoid arthritis.
Long-term outcome data are critical for a comprehensive understanding of biosimilar utility and impact.